Apogee Therapeutics, Inc.
APGE
$82.93
-$1.67-1.97%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -74.11M | -69.39M | -65.02M | -66.10M | -55.34M |
| Total Depreciation and Amortization | 408.00K | 406.00K | 406.00K | 399.00K | 207.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.59M | 11.15M | 11.20M | 10.51M | 9.60M |
| Change in Net Operating Assets | 1.55M | -4.86M | -837.00K | -6.84M | -2.95M |
| Cash from Operations | -55.57M | -62.69M | -54.26M | -62.03M | -48.48M |
| Capital Expenditure | -- | -62.00K | 0.00 | -768.00K | -4.32M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.35M | -288.56M | 17.95M | 78.89M | 17.30M |
| Cash from Investing | -35.35M | -288.63M | 17.95M | 78.13M | 12.98M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 411.17M | 374.95M | 19.74M | 1.18M | 622.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 411.17M | 374.95M | 19.74M | 1.18M | 622.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 320.25M | 23.64M | -16.57M | 17.28M | -34.87M |